Research at Korea Research Institute of Chemical Technology (KRICT) has led to the identification of pyrazolopyrimidine-containing compounds acting as dual specificity protein kinase TTK (MPS1; MPS1L1) inhibitors and reported to be useful for the treatment of cancer.